Comparison of prophylactic effect versus therapeutic effect of amiodarone in patients undergoing heart surgery at risk of atrial fibrillation

Comparison of prophylactic effect versus therapeutic effect of amiodarone in patients undergoing heart surgery at risk of atrial fibrillation: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N392

Enrollment

200

Registered

2021-05-02

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation. Unspecified atrial fibrillation

Interventions

Intervention 1: Intervention group: Intravenous infusion of amiodarone (manufactured by Shahr Daroo Pharmaceutical Co.) 350 mg 24 hours before surgery. Intervention 2: Control group: Intravenous infus

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age: 18 to 65 years old Candidate for elective cardiac surgery Having a preoperative sinus rhythm

Exclusion criteria

Exclusion criteria: Use of antihypertensive drugs other than beta-blockers or ACE inhibitors Thyroid, renal, pulmonary, hepatic disorders Asthma Bradycardia Heart failure Atrioventricular block Sensitivity to amiodarone

Design outcomes

Primary

Measure	Time frame
Incidence of atrial fibrillation. Timepoint: 24 hours after surgery. Method of measurement: Using a monitor machine.	—

Secondary

Measure	Time frame
Incidence of side effects (such as hypotension and bradycardia). Timepoint: 24 hours after surgery. Method of measurement: using a monitor machine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mehran Jabari Mehrabani

Hamedan University of Medical Sciences

mehran_jabbari@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026